Pulmonx Q2 revenue up 15%, beats expectations, cuts FY revenue forecast

Pulmonx

30/07/2025 21:14

Overview

Pulmonx Q2 revenue rises 15% yr/yr to $23.9 mln, beating analyst expectations

International revenue grows 32% yr/yr, while U.S. revenue increases 6%

Company revises full-year revenue guidance downwards due to U.S. revenue conversion delays

Outlook

Pulmonx lowers 2025 revenue guidance to $90 mln-$92 mln

Company expects 2025 gross margin to be about 74%

Pulmonx revises 2025 operating expenses to $128 mln-$130 mln

Company's guidance excludes impact from future tariffs or trade changes

Result Drivers

INTERNATIONAL PERFORMANCE - Strong international revenue growth of 32% yr/yr contributed significantly to overall revenue increase

ADVERTISING IMPACT - Targeted Direct-to-Patient advertising drove over 20,000 first-time patient engagements

EXPANSION - Addition of 12 new U.S. treatment centers and training of 26 new physicians supported growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$23.86 mln
$23.50 mln (6 Analysts)
Q2 EPS
-$0.38
Q2 Net Income
-$15.17 mln
Q2 Gross Profit
$17.20 mln
Q2 Income From Operations
-$14.80 mln
Q2 Pretax Profit
-$15 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Pulmonx Corp is $13.50, about 77.1% above its July 29 closing price of $3.09

Press Release: ID:nGNX6yq7bK

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)